Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
1. Gild announced partnership to supply lenacapavir for HIV prevention globally. 2. Supply aims to reach two million people in supported countries at no profit. 3. Lenacapavir, approved as PrEP, offers groundbreaking treatment options. 4. Funding uncertainties pose challenges for Global Fund's ability to purchase doses. 5. GILD shares rose 1.26% following the announcement.